Late Relapse of Testicular Germ Cell Tumors

Urologic Clinics of North America

Volumn 42, Issue 3, 2015, Pages 359-368

  O'Shaughnessy, Matthew J ^a   Feldman, Darren R ^a   Carver, Brett S ^a   Sheinfeld, Joel ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Germ cell tumor; Late relapse; Retroperitoneal lymph node dissection

Indexed keywords

ALPHA FETOPROTEIN; BLEOMYCIN; CHORIONIC GONADOTROPIN; CISPLATIN; ETOPOSIDE; IFOSFAMIDE; PACLITAXEL; ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; FOLLOW UP; GERM CELL TUMOR; HISTOPATHOLOGY; HUMAN; LYMPH NODE DISSECTION; NON SEMINOMATOUS GERMINOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEMINOMA; TESTICULAR GERM CELL TUMOR; TESTIS CANCER; DISEASE MANAGEMENT; LYMPH NODE; LYMPH NODE METASTASIS; MALE; MINIMAL RESIDUAL DISEASE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GERM CELL AND EMBRYONAL; PATHOLOGY; PATHOPHYSIOLOGY; RETROPERITONEUM; SECONDARY PREVENTION; SURGERY; TESTICULAR NEOPLASMS; TIME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE MANAGEMENT; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASM, RESIDUAL; NEOPLASMS, GERM CELL AND EMBRYONAL; PROGNOSIS; RETROPERITONEAL SPACE; SECONDARY PREVENTION; TESTICULAR NEOPLASMS; TIME FACTORS;

EID: 84938289873     PISSN: 00940143     EISSN: 1558318X     Source Type: Journal    
DOI: 10.1016/j.ucl.2015.04.010     Document Type: Review

References (59)

1. Sheinfeld J., Herr H.W. Role of surgery in management of germ cell tumor. Semin Oncol 1998, 25:203-209.
2. Einhorn L.H. Testicular cancer as a model for a curable neoplasm: The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1981, 41:3275-3280.
3. Baniel J., Foster R.S., Gonin R., et al. Late relapse of testicular cancer. J Clin Oncol 1995, 13:1170-1176.
4. Ravi R., Oliver R.T., Ong J., et al. A single-centre observational study of surgery and late malignant events after chemotherapy for germ cell cancer. Br J Urol 1997, 80:647-652.
5. Gerl A., Clemm C., Schmeller N., et al. Late relapse of germ cell tumors after cisplatin-based chemotherapy. Ann Oncol 1997, 8:41-47.
6. Shahidi M., Norman A.R., Dearnaley D.P., et al. Late recurrence in 1263 men with testicular germ cell tumors. Multivariate analysis of risk factors and implications for management. Cancer 2002, 95:520-530.
7. Dieckmann K.P., Albers P., Classen J., et al. Late relapse of testicular germ cell neoplasms: a descriptive analysis of 122 cases. J Urol 2005, 173:824-829.
8. Ronnen E.A., Kondagunta G.V., Bacik J., et al. Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy. J Clin Oncol 2005, 23:6999-7004.
9. Oldenburg J., Alfsen G.C., Waehre H., et al. Late recurrences of germ cell malignancies: a population-based experience over three decades. Br J Cancer 2006, 94:820-827.
10. Oldenburg J., Martin J.M., Fossa S.D. Late relapses of germ cell malignancies: incidence, management, and prognosis. J Clin Oncol 2006, 24:5503-5511.
11. Carver B.S., Motzer R.J., Kondagunta G.V., et al. Late relapse of testicular germ cell tumors. Urol Oncol 2005, 23:441-445.
12. George D.W., Foster R.S., Hromas R.A., et al. Update on late relapse of germ cell tumor: a clinical and molecular analysis. J Clin Oncol 2003, 21:113-122.
13. Geldart T.R., Gale J., McKendrick J., et al. Late relapse of metastatic testicular nonseminomatous germ cell cancer: surgery is needed for cure. BJU Int 2006, 98:353-358.
14. Sharp D.S., Carver B.S., Eggener S.E., et al. Clinical outcome and predictors of survival in late relapse of germ cell tumor. J Clin Oncol 2008, 26:5524-5529.
15. Motzer R.J., Agarwal N., Beard C., et al. Testicular cancer. J Natl Compr Canc Netw 2012, 10:502-535.
16. Tarin T.V., Sonn G., Shinghal R. Estimating the risk of cancer associated with imaging related radiation during surveillance for stage I testicular cancer using computerized tomography. J Urol 2009, 181:627-632. [discussion: 632-3].
17. Tandstad T., Dahl O., Cohn-Cedermark G., et al. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J Clin Oncol 2009, 27:2122-2128.
18. O'Malley M.E., Chung P., Haider M., et al. Comparison of low dose with standard dose abdominal/pelvic multidetector CT in patients with stage 1 testicular cancer under surveillance. Eur Radiol 2010, 20:1624-1630.
19. Martin J.M., Panzarella T., Zwahlen D.R., et al. Evidence-based guidelines for following stage 1 seminoma. Cancer 2007, 109:2248-2256.
20. DeLeo M.J., Greco F.A., Hainsworth J.D., et al. Late recurrences in long-term survivors of germ cell neoplasms. Cancer 1988, 62:985-988.
21. Kollmannsberger C., Tandstad T., Bedard P.L., et al. Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance. J Clin Oncol 2015, 33:51-57.
22. Warde P., Specht L., Horwich A., et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol 2002, 20:4448-4452.
23. Chung P., Parker C., Panzarella T., et al. Surveillance in stage I testicular seminoma-risk of late relapse. Can J Urol 2002, 9:1637-1640.
24. Gels M.E., Hoekstra H.J., Sleijfer D.T., et al. Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: a single-center 10-year experience. J Clin Oncol 1995, 13:1188-1194.
25. Sogani P.C., Perrotti M., Herr H.W., et al. Clinical stage I testis cancer: long-term outcome of patients on surveillance. J Urol 1998, 159:855-858.
26. Kollmannsberger C., Moore C., Chi K.N., et al. Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy. Ann Oncol 2010, 21:1296-1301.
27. Rice K.R., Beck S.D., Pedrosa J.A., et al. Surgical management of late relapse on surveillance in patients presenting with clinical stage I testicular cancer. Urology 2014, 84:886-890.
28. Mead G.M., Fossa S.D., Oliver R.T., et al. Randomized trials in 2466 patients with stage I seminoma: patterns of relapse and follow-up. J Natl Cancer Inst 2011, 103:241-249.
29. Jones W.G., Fossa S.D., Mead G.M., et al. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I testicular seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol 2005, 23:1200-1208.
30. Fossa S.D., Horwich A., Russell J.M., et al. Optimal planning target volume for stage I testicular seminoma: a Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. J Clin Oncol 1999, 17:1146.
31. Oliver R.T., Mason M.D., Mead G.M., et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet 2005, 366:293-300.
32. Kollmannsberger C., Tyldesley S., Moore C., et al. Evolution in management of testicular seminoma: population-based outcomes with selective utilization of active therapies. Ann Oncol 2011, 22:808-814.
33. Warde P., Gospodarowicz M.K., Panzarella T., et al. Stage I testicular seminoma: results of adjuvant irradiation and surveillance. J Clin Oncol 1995, 13:2255-2262.
34. Hallemeier C.L., Choo R., Davis B.J., et al. Excellent long-term disease control with modern radiotherapy techniques for stage I testicular seminoma-the Mayo Clinic experience. Urol Oncol 2014, 32:24.e1-24.e6.
35. Powles T., Robinson D., Shamash J., et al. The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis. Ann Oncol 2008, 19:443-447.
36. Stephenson A.J., Bosl G.J., Motzer R.J., et al. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome. J Clin Oncol 2005, 23:2781-2788.
37. Donohue J.P., Thornhill J.A., Foster R.S., et al. Primary retroperitoneal lymph node dissection in clinical stage A non-seminomatous germ cell testis cancer. Review of the Indiana University experience 1965-1989. Br J Urol 1993, 71:326-335.
38. Eggener S.E., Carver B.S., Sharp D.S., et al. Incidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer. J Urol 2007, 177:937-942. [discussion: 942-3].
39. Carver B.S., Shayegan B., Eggener S., et al. Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol 2007, 25:4365-4369.
40. Lutke Holzik M.F., Hoekstra H.J., Mulder N.H., et al. Non-germ cell malignancy in residual or recurrent mass after chemotherapy for nonseminomatous testicular germ cell tumor. Ann Surg Oncol 2003, 10:131-135.
41. Tandstad T., Stahl O., Hakansson U., et al. One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group. Ann Oncol 2014, 25:2167-2172.
42. Rabbani F., Sheinfeld J., Farivar-Mohseni H., et al. Low-volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: pattern and prognostic factors for relapse. J Clin Oncol 2001, 19:2020-2025.
43. Donohue J.P., Thornhill J.A., Foster R.S., et al. Clinical stage B non-seminomatous germ cell testis cancer: the Indiana University experience (1965-1989) using routine primary retroperitoneal lymph node dissection. Eur J Cancer 1995, 31A:1599-1604.
44. Kondagunta G.V., Sheinfeld J., Mazumdar M., et al. Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy. J Clin Oncol 2004, 22:464-467.
45. Ehrlich Y., Brames M.J., Beck S.D., et al. Long-term follow-up of cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission?. J Clin Oncol 2010, 28:531-536.
46. Stephenson A.J., Bosl G.J., Motzer R.J., et al. Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer. J Clin Oncol 2007, 25:5597-5602.
47. Kondagunta G.V., Bacik J., Bajorin D., et al. Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors. J Clin Oncol 2005, 23:9290-9294.
48. Fossa S.D., Ous S., Lien H.H., et al. Post-chemotherapy lymph node histology in radiologically normal patients with metastatic nonseminomatous testicular cancer. J Urol 1989, 141:557-559.
49. Toner G.C., Panicek D.M., Heelan R.T., et al. Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. J Clin Oncol 1990, 8:1683-1694.
50. Logothetis C.J., Samuels M.L., Trindade A., et al. The growing teratoma syndrome. Cancer 1982, 50:1629-1635.
51. Motzer R.J., Amsterdam A., Prieto V., et al. Teratoma with malignant transformation: diverse malignant histologies arising in men with germ cell tumors. J Urol 1998, 159:133-138.
52. Carver B.S., Bianco F.J., Shayegan B., et al. Predicting teratoma in the retroperitoneum in men undergoing post-chemotherapy retroperitoneal lymph node dissection. J Urol 2006, 176:100-103. [discussion: 103-4].
53. Michael H., Lucia J., Foster R.S., et al. The pathology of late recurrence of testicular germ cell tumors. Am J Surg Pathol 2000, 24:257-273.
54. Motzer R.J., Sheinfeld J., Mazumdar M., et al. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol 2000, 18:2413-2418.
55. Gerl A., Wilmanns W. Antitumor activity of paclitaxel after failure of high-dose chemotherapy in a patient with late relapse of a non-seminomatous germ cell tumor. Anticancer Drugs 1996, 7:716-718.
56. Bedano P.M., Brames M.J., Williams S.D., et al. Phase II study of cisplatin plus epirubicin salvage chemotherapy in refractory germ cell tumors. J Clin Oncol 2006, 24:5403-5407.
57. Feldman D.R., Sheinfeld J., Bajorin D.F., et al. TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J Clin Oncol 2010, 28:1706-1713.
58. Lorch A., Kollmannsberger C., Hartmann J.T., et al. Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group. J Clin Oncol 2007, 25:2778-2784.
59. Lorch A., Rick O., Wundisch T., et al. High dose chemotherapy as salvage treatment for unresectable late relapse germ cell tumors. J Urol 2010, 184:168-173.